Announced
Completed
Financials
Sources
Tags
France
Private
Acquisition
Friendly
Majority
cell and gene therapy
Single Bidder
Completed
Medical Supplies
Cross Border
Synopsis
SK Group completed the acquisition of YpoKesi, a producer of gene and cell therapy products. Financial terms were not disclosed. "We are glad to advance into the gene therapy CMO business by investing in Yposkesi which has great capability and potential. We will spare no efforts to help Yposkesi grow fast in the global market," Jang Dong-Hyun, SK Group CEO.
© COPYRIGHT 2024 MERGERLINKS LIMITED.
ALL RIGHTS RESERVED.
15 BONHILL STREET, LONDON, EC2A 4DN, UNITED KINGDOM.